H11-Alb-hTTR*V50M Mouse
Product Name
H11-Alb-hTTR*V50M Mouse
Product ID
C001525
Strain Name
C57BL/6NCya-Igs2em1(Alb-hTTR*V50M)/Cya
Backgroud
C57BL/6NCya
Note
One of Cyagen's HUGO-GT® (Humanized Genomic Ortholog for Gene Therapy) Mouse Strains
When using this mouse strain in a publication, please cite “H11-Alb-hTTR*V50M Mouse (Catalog C001525) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
CTS, TTN, ATTR, CTS1, PALB, TBPA, HEL111, HsT2651
NCBI ID
Chromosome
Chr 18
MGI ID
Datasheet
Strain Description
Transthyretin amyloidosis (ATTR) is a protein misfolding disorder caused by the abnormal accumulation of misfolded transthyretin (TTR) protein in organs and tissues throughout the body. It primarily affects the peripheral nervous system and the heart [1]. Hereditary ATTR (ATTRv) results from genetic mutations in the TTR gene. The TTR gene encodes transthyretin, also known as prealbumin. This protein is primarily synthesized in the liver, with a smaller amount produced in the choroid plexus of the brain or the light-sensitive tissue in the eye (such as the retina). TTR functions as a transport protein and normally exists in the peripheral blood as a homotetramer, participating in the transport of thyroid hormones and retinol-binding protein.
Over 130 TTR variants have been identified, among which the Val50Met (V50M) mutation, also known as c.148G>A and V30M, is the most common in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) [2-6]. Most ATTRv patients with the Val50Met mutation, if left untreated, will progress to complete disability or even death within 10 to 15 years after diagnosis. Their neurological symptoms may also be accompanied by gastrointestinal dysfunction, cardiomyopathy, renal disease, or ocular deposits [7].
The primary treatment for ATTR mainly involves inhibiting the production of mutant TTR gene mRNA or stabilizing the structure of TTR protein tetramers. In the current stage of research targeting TTR, several innovative therapeutic pipelines have emerged, including ASO (antisense oligonucleotide) drugs, siRNA drugs, and CRISPR-based gene therapies. Inotersen Sodium, developed by the leading nucleic acid drug company Ionis, specifically targets the conservative sequence in the 3’ untranslated region of TTR mRNA, inducing mRNA degradation to reduce TTR synthesis in liver cells. It is the first ASO drug approved for this disease [8]. Given that most ASO, siRNA, and CRISPR-based therapies target the human TTR gene, humanizing mouse genes can accelerate the TTR-targeted treatments into clinical stages.
This strain is a Ttr humanized model and can be used for research on ATTRv-PN. A human TTR gene fragment carrying the V50M mutation, driven by the mouse Alb promoter (liver-specific promoter), is inserted at the H11 safe harbor. This modification does not affect the expression of the mouse Ttr gene. The homozygous H11-Alb-hTTR*V50M mice are viable and fertile. In addition, based on the independently developed TurboKnockout fusion BAC recombination technology, Cyagen can also provide customized services to meet experimental needs.
Reference
Saraiva M J M ,Birken S, Costa P P, et al. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin)[J]. Journal of Clinical Investigation, 1984, 74(1):104-119.
Jacobson D R, Mcfarlin D E, Kane I, et al. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement[J]. 1992, 89(3):353-356.
Tongtong Cui, Bojin Li, Wei Li, NTLA-2001: opening a new era for gene therapy, Life Medicine, Volume 1, Issue 2, October 2022, Pages 49–51.
Paula Gonçalves, Helena Martins, Susete Costelha, Luis F. Maia & Maria Joao Saraiva (2016) Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model, Amyloid, 23:4, 249-253.
Habtemariam BA, Karsten V, Attarwala H, Goel V, Melch M, Clausen VA, Garg P, Vaishnaw AK, Sweetser MT, Robbie GJ, Vest J. Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clin Pharmacol Ther. 2021 Feb;109(2):372-382.
Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003 Sep;10(3):160-84.
Keam, S.J. Inotersen: First Global Approval. Drugs 78, 1371–1376 (2018).
Strain Strategy
The Alb promoter-Human TTR Genomic DNA (exon 1 to downstream of exon 4) cassette was inserted into the H11 locus (upstream of the Eif4enif1 gene and downstream of the Drg1 gene). The p.V50M (GTG to ATG) point mutation was introduced into human TTR exon 2.
Figure 1. Gene editing strategy of H11-Alb-hTTR*V50M mice.
Application Area
Research on hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN);
Preclinical evaluation of TTR-targeted drugs.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.